Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:ONNVF)

0.6180 UNCHANGED
Last Price Updated: 9:52 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ONNVF

< Previous 1 2 3 Next >
News headline image
Onco-Innovations Announces Non-Brokered LIFE Offering
From Onco-Innovations Limited
Via ACCESS Newswire
News headline image
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
From Onco-Innovations Limited
Via ACCESS Newswire
InvestorNewsBreaks – Why Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
From Onco-Innovations Limited
Via ACCESS Newswire
Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development
Via Investor Brand Network
News headline image
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Via ACCESS Newswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance
Via Investor Brand Network
News headline image
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Via ACCESS Newswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances Kilogram-Scale Manufacturing for ONC010 Program
Via Investor Brand Network
News headline image
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Via ACCESS Newswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Advances Manufacturing Scale-Up for Lead Oncology Candidate ONC010
Via Investor Brand Network
News headline image
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
Via ACCESS Newswire
News headline image
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Via ACCESS Newswire
News headline image
Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
Via ACCESS Newswire
News headline image
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Via ACCESS Newswire
News headline image
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Via ACCESS Newswire
News headline image
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Via ACCESS Newswire
News headline image
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Via ACCESS Newswire
News headline image
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
From OneMedNet Corporation
Via GlobeNewswire
News headline image
Onco-Innovations Announces Closing of Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Amendment to Private Placement Pricing
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Via ACCESS Newswire
News headline image
Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services
Via ACCESS Newswire
News headline image
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
Via ACCESS Newswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.